---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-065292"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:37:32.514397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL

## Summary
- First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.
- Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).
- Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).
- Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.
- Clinical trial identifier on ClinicalTrials.gov: NCT06343311.

## SEC filing metadata
- accession: 0001213900-24-065292
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/0001213900-24-065292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/ea021066101-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-065292
- JSON: https://secwatch.observer/filing/0001213900-24-065292.json
- Plain text: https://secwatch.observer/filing/0001213900-24-065292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.